2018 American Transplant Congress
Induction Agents and Post-Transplant Malignancies in Kidney Transplants: An Examination of Outcomes at a Large Volume Center over 20 Years
Division of Transplant Surgery, University of Wisconsin, Madison, WI.
Introduction: Induction agents have a profound effect on the immune milieu at the time of kidney transplantation. However, evaluation of their long-term effects on graft…2018 American Transplant Congress
Optimal Anti-Thymocyte Globulin Dose for Induction Immunosuppression in Kidney Transplantation
Organ Transplant Program, Swedish Medical Center, Seattle, WA.
Anti-thymocyte globulin (ATG) is used as induction immunosuppression in kidney transplantation to prevent allograft rejection. ATG causes dose-dependent lymphocyte depletion, yet optimal dose is unknown.…2018 American Transplant Congress
Hepatitis C Recurrence after Liver Transplant: A Comparison of Antibody Induction versus No Antibody Induction
University of Illinois Hospital and Health Sciences System, Chicago.
Background: Hepatitis C virus (HCV) recurrence after orthotopic liver transplant (OLT) is universal and exhibits accelerated progression to cirrhosis. Progression can be mitigated by new…2018 American Transplant Congress
Islet Xenotransplantation: A Quest for Clinically Available Immunosuppression Regimens
Department of Surgery, Duke University Medical Center, Durham, NC.
IntroductionThe field of porcine islet xenotransplantation has made significant progress in non-human primate studies in recent years. However, one major barrier preventing clinical translation of…2018 American Transplant Congress
T Cell Exhaustion in Kidney Transplant Patients
Background: T cell exhaustion is a dysfunctional state that arises during chronic infection and cancer in response to persistence of high antigenic load. Whether chronic…2018 American Transplant Congress
Risk of Bacteremia According to Transplant Induction Immunosuppression Regimen
University of Wisconsin School of Medicine and Public Health, Madison.
Background: Transplant immune suppression is designed to suppress the adaptive immune response and ensure graft survival, but may have unintended effects on innate immunity. Few…2018 American Transplant Congress
The BEST Trial: A Prospective Randomized Multicenter Trial of Belatacept-Based CNI- and Corticosteroid-Free Immunosuppression
Previous large multicenter belatacept (BELA)-based CNI- and steroid-free immunosuppressive trials have not enrolled to completion due to safety concerns. The BEST Trial (Belatacept-based Early Steroid…2018 American Transplant Congress
B Cell Reconstitution: 36-Month Analysis of Patients Post-Alemtuzumab Induction Followed by Belatacept-Based Immunosuppression
Alemtuzumab induction combined with belatacept and rapamycin (ABR) maintenance immunotherapy effectively prevents costimulation blockade resistant rejection (CoBRR). We longitudinally investigated kinetics of repopulating B cell…2018 American Transplant Congress
A Comparison of Alemtuzumab versus Antithymocyte Globulin Induction in High-Risk, Non-Sensitized Renal Transplant Recipients
University of Illinois Hospital and Health Sciences System, Chicago.
Background: Lymphocyte depleting induction is routinely utilized in high immunologic risk renal transplant (RTx). African Americans (AA) have a relatively higher risk of rejection regardless…2018 American Transplant Congress
Comparing Outcomes between Induction Immunosuppressive Therapies in Simultaneous Heart/Kidney Transplantation
Virginia Commonwealth University, Richmond.
Introduction: There is no published data on the risks and benefits of Induction immunosuppression in simultaneous heart/kidney transplant (SHKT) patients.Methods: We analyzed all SHKT performed…
- « Previous Page
- 1
- …
- 14
- 15
- 16
- 17
- 18
- …
- 31
- Next Page »